Betta Pharmaceuticals Co., Ltd. (SHE:300558)

Betta Pharmaceuticals Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Jan 1, 2022	Dec 31, 2020
Operating Revenue	3,200	2,827	2,417	2,342	2,206	1,824
Other Revenue	64.95	64.95	39.41	34.18	40.05	46.19
Revenue	3,265	2,892	2,456	2,377	2,246	1,870
Revenue Growth (YoY)	18.40%	17.74%	3.35%	5.82%	20.08%	20.36%
Cost of Revenue	693.15	538.52	404.48	268.69	174.44	138.9
Gross Profit	2,571	2,353	2,052	2,108	2,071	1,731
Selling, General & Admin	1,499	1,363	1,116	1,234	1,141	946.77
Research & Development	490.83	501.9	640.14	699.9	565.95	362.85
Other Operating Expenses	59.38	18.19	10.62	-34.51	15.24	6.99
Operating Expenses	2,049	1,876	1,772	1,901	1,723	1,317
Operating Income	522.43	476.96	279.88	206.96	348.77	414.79
Interest Expense	-71.46	-45.49	-54.95	-195.8	-15.78	-39.86
Interest & Investment Income	5.58	6.78	10.23	10.88	33.35	298.46
Currency Exchange Gain (Loss)	4.14	4.14	6.72	9.55	-3.63	-8.42
Other Non Operating Income (Expenses)	5.13	-1.45	-4.96	-9	-0.84	2.03
EBT Excluding Unusual Items	465.82	440.94	236.92	22.59	361.88	666.99
Gain (Loss) on Sale of Investments	-139.21	-40.97	-13.67	-20.62	1.01	-12.42
Gain (Loss) on Sale of Assets	-0.64	-0.59	-0.01	88.61	0.07	-1.7
Asset Writedown	-28.05	-28.05	-1.07	-3.01	-0.03	-
Other Unusual Items	55.99	22.83	99.9	-	27.01	13.79
Pretax Income	353.91	394.16	322.07	87.57	389.93	666.66
Income Tax Expense	69.08	7.18	-11.54	-37.19	10.37	65.58
Earnings From Continuing Operations	284.83	386.98	333.62	124.76	379.56	601.09
Minority Interest in Earnings	18.44	15.59	14.42	20.66	3.51	5.27
Net Income	303.28	402.57	348.03	145.42	383.07	606.36
Net Income to Common	303.28	402.57	348.03	145.42	383.07	606.36
Net Income Growth	-34.01%	15.67%	139.33%	-62.04%	-36.83%	162.70%
Shares Outstanding (Basic)	417	419	419	416	416	404
Shares Outstanding (Diluted)	421	419	419	416	416	407
Shares Change (YoY)	-0.15%	0.01%	0.72%	-0.02%	2.32%	1.09%
EPS (Basic)	0.73	0.96	0.83	0.35	0.92	1.50
EPS (Diluted)	0.72	0.96	0.83	0.35	0.92	1.49
EPS Growth	-33.91%	15.66%	137.47%	-62.01%	-38.26%	161.40%
Free Cash Flow	46.98	83.58	-181.79	-703.8	-231.75	-39.81
Free Cash Flow Per Share	0.11	0.20	-0.43	-1.69	-0.56	-0.10
Dividend Per Share	0.200	0.200	0.170	0.070	0.250	0.310
Dividend Growth	17.65%	17.65%	142.86%	-72.00%	-19.36%	63.16%
Gross Margin	78.77%	81.38%	83.53%	88.69%	92.23%	92.57%
Operating Margin	16.00%	16.49%	11.39%	8.71%	15.53%	22.18%
Profit Margin	9.29%	13.92%	14.17%	6.12%	17.06%	32.42%
Free Cash Flow Margin	1.44%	2.89%	-7.40%	-29.61%	-10.32%	-2.13%
EBITDA	942.98	845.1	578.14	453.58	517.89	569.95
EBITDA Margin	28.88%	29.22%	23.54%	19.09%	23.06%	30.47%
D&A For EBITDA	420.55	368.14	298.26	246.62	169.12	155.16
EBIT	522.43	476.96	279.88	206.96	348.77	414.79
EBIT Margin	16.00%	16.49%	11.39%	8.71%	15.53%	22.18%
Effective Tax Rate	19.52%	1.82%	-	-	2.66%	9.84%
Revenue as Reported	3,265	2,892	2,456	2,377	2,246	1,870
Advertising Expenses	-	-	-	414.75	459.29	376.61

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.